Montelukast Teva (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for maintenance therapy of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet global healthcare needs. Our distribution network ensures reliable delivery across continents.

Montelukast acts on the leukotriene pathway to control airway inflammation and allergic symptoms.

Asthma (maintenance therapy): reduces frequency of bronchospasm episodes and improves overall lung function. Allergic rhinitis: alleviates nasal congestion, sneezing, itching and watery discharge. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Abdominal pain: discomfort in the stomach area, usually resolves. - Cough: dry or productive, may be related to underlying condition. - Nausea: feeling of queasiness, sometimes accompanied by vomiting.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis requiring immediate medical attention. - Neuropsychiatric events: agitation, depression, anxiety, or suicidal thoughts reported in rare cases. - Hepatic dysfunction: elevated liver enzymes or hepatitis, necessitating monitoring.

Before initiating Montelukast therapy, consider the following precautions to ensure safe use.

Assess liver function: monitor patients with hepatic impairment as metabolism occurs in the liver. Review psychiatric history: be alert for mood changes or suicidal thoughts, especially in adolescents. Evaluate concomitant medications: avoid use with strong enzyme inducers that may reduce efficacy. Consider age restrictions: safety and efficacy have been established for specific pediatric age groups. Counsel on adherence: consistent daily dosing maximizes therapeutic benefit. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Phenobarbital, carbamazepine, phenytoin: strong enzyme inducers that can markedly lower montelukast plasma concentrations. - Ritonavir: potent CYP3A4 inhibitor that may increase montelukast exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Fluconazole: moderate CYP3A4 inhibition may raise montelukast levels. - Rifampin: enzyme induction may reduce therapeutic effect. - Warfarin: possible alteration of anticoagulant effect; monitor INR. - Oral contraceptives: may slightly increase montelukast levels, generally not clinically significant.